187 related articles for article (PubMed ID: 27956153)
1. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
2. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
5. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
6. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
7. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
8. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
9. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
[TBL] [Abstract][Full Text] [Related]
10. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
11. [Dynamics of postinfarction left ventricular remodeling during long term use of perindopril, amiodarone, and beta-adrenoblockers].
Kanorskiĭ SG; Staritskiĭ AG; Bozhko AA
Kardiologiia; 2005; 45(3):31-5. PubMed ID: 15821705
[TBL] [Abstract][Full Text] [Related]
12. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
[TBL] [Abstract][Full Text] [Related]
13. Impact of the β-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between β adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study.
Lee HY; Chung WJ; Jeon HK; Seo HS; Choi DJ; Jeon ES; Kim JJ; Shin JH; Kang SM; Lim SC; Baek SH
Korean J Intern Med; 2016 Mar; 31(2):277-87. PubMed ID: 26879662
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
15. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
[TBL] [Abstract][Full Text] [Related]
16. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
[TBL] [Abstract][Full Text] [Related]
18. MY APPROACH to the patient with heart failure and improved ejection fraction
Cohn JN
Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
[No Abstract] [Full Text] [Related]
19. The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure.
van de Ven LL; van Veldhuisen DJ; Goulder M; Zilahi Z; Meyer WR; Willenheimer R
Int J Cardiol; 2010 Sep; 144(1):59-63. PubMed ID: 19481278
[TBL] [Abstract][Full Text] [Related]
20. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.
Kalam K; Marwick TH
Eur J Cancer; 2013 Sep; 49(13):2900-9. PubMed ID: 23706982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
